Compare · Head-to-head
Liraglutide vs MOTS-c.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Liraglutide, then use the table to confirm fit.
Liraglutide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | Liraglutide | MOTS-c |
|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | fat loss & metabolism and longevity & anti-aging comparisons |
| Evidence | Tier A | Tier C |
| Risk | medium | high |
| Experience level | intermediate | advanced |
| Budget tier | premium | premium |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Liraglutide | MOTS-c |
|---|---|---|
| Goal fit | Fat Loss & Metabolism | Fat Loss & Metabolism, Longevity & Anti-Aging |
| What users compare it for | Moderate weight loss, improved satiety, and HbA1c reduction in clinical populations. | Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice. |
| Onset timeline | Metabolic and appetite effects begin within days to weeks; body-weight effects build over months. | Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Liraglutide | MOTS-c |
|---|---|---|
| Adverse effects | GI effects are common, especially nausea, vomiting, constipation, and diarrhea. Pancreatitis and gallbladder events remain class concerns. | FDA: no identified human exposure data; significant immunogenicity/characterization risks. |
| Contraindications | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history and pregnancy. | No human data. |
| Interaction notes | Same class cautions as other GLP-1 agents: hypoglycemia risk rises with insulin or sulfonylureas, and gastric emptying delay can affect oral medications. | Unknown. |
| Regulatory status | Prescription-approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | Status unclear |
04 · Age & monitoring
| Decision factor | Liraglutide | MOTS-c |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64, 65+ | No age guidance yet |
| Life-stage note | Adult metabolic-health use case with the strongest fit when evidence and regulatory clarity matter more than novelty. | Not yet documented |
| Monitoring burden | medium | Not specified |
| Follow-up cadence | Early review in the first month, then periodic follow-up every few months. | Not yet documented |
05 · Cost & sourcing
| Decision factor | Liraglutide | MOTS-c |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | €33.02 |
| Estimated monthly cost | No reliable estimate yet | €33.02 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Liraglutide | MOTS-c |
|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.